Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 29:8:359-66.
doi: 10.2147/IDR.S62119. eCollection 2015.

Delamanid expanded access novel treatment of drug resistant tuberculosis

Roxana Rustomjee  1 , Alimuddin Zumla  2
Affiliations
Review

Delamanid expanded access novel treatment of drug resistant tuberculosis

Roxana Rustomjee et al. Infect Drug Resist. .

Erratum in

Abstract

Tuberculosis (TB) remains a global emergency and is one of the most common infectious disease causes of death in developing countries. Current treatment regimens for multi-drug resistant TB are associated with low treatment success rates, are toxic, and require long duration of treatment. The need for shorter and more effective treatment regimens is urgent. Delamanid (Deltyba, or formerly known as OPC-67683) is a new dihydro-imidazooxazole anti-TB drug active against resistant forms of pulmonary TB. Delamanid kills Mycobacterium tuberculosis by inhibiting the synthesis of mycolic acids required for cell wall synthesis. Whilst delamanid has been included in the WHO Model List of Essential Medicine by the World Health Organization Expert Committee on Selection and Use of Essential Medicines and in international guidance for the treatment of multi-drug resistant TB since April 2014, its access in countries with the greatest need, has proven challenging. This review provides an update on currently available clinical safety and efficacy data on delamanid and offers a discussion on research priorities and recommendations for expedited, expanded access.

Keywords: MDR-TB; delamanid; drug resistance; expanded access; tuberculosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization . Global tuberculosis report 2014. Geneva: World Health Organization; 2014. [Accessed September 27, 2015]. Available from: http://www.who.int/tb/publications/global_report/en/
    1. Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015;3(3):220–234. - PubMed
    1. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010;375(9731):2100–2109. - PubMed
    1. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466. - PMC - PubMed
    1. World Health Organization . The Selection and Use of Essential Medicine Report: 20–24 April, 2015. Geneva: World Health Organization; [Accessed June 6, 2015]. Available from: http://www.who.int/medicines/publications/essential-medicines/Executive-....